BRPI0414845B8 - mólecula de ácido nucleico, vetor, célula de levedura, partícula semelhante a vírus, bem como método para produzir a dita partícula semelhante a vírus - Google Patents

mólecula de ácido nucleico, vetor, célula de levedura, partícula semelhante a vírus, bem como método para produzir a dita partícula semelhante a vírus

Info

Publication number
BRPI0414845B8
BRPI0414845B8 BRPI0414845A BRPI0414845A BRPI0414845B8 BR PI0414845 B8 BRPI0414845 B8 BR PI0414845B8 BR PI0414845 A BRPI0414845 A BR PI0414845A BR PI0414845 A BRPI0414845 A BR PI0414845A BR PI0414845 B8 BRPI0414845 B8 BR PI0414845B8
Authority
BR
Brazil
Prior art keywords
virus
particle
hpv45
vector
particles
Prior art date
Application number
BRPI0414845A
Other languages
English (en)
Portuguese (pt)
Inventor
T Bryan Janine
U Jansen Kathrin
D Schultz Loren
K Brownlow Michelle
Original Assignee
Merck Sharp & Dohme
Merck & Co Inc
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme, Merck & Co Inc, Schering Corp filed Critical Merck Sharp & Dohme
Publication of BRPI0414845A publication Critical patent/BRPI0414845A/pt
Publication of BRPI0414845B1 publication Critical patent/BRPI0414845B1/pt
Publication of BRPI0414845B8 publication Critical patent/BRPI0414845B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
BRPI0414845A 2003-09-29 2004-09-24 mólecula de ácido nucleico, vetor, célula de levedura, partícula semelhante a vírus, bem como método para produzir a dita partícula semelhante a vírus BRPI0414845B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50681203P 2003-09-29 2003-09-29
US60/506,812 2003-09-29
PCT/US2004/031326 WO2005032586A1 (en) 2003-09-29 2004-09-24 Optimized expression of hpv 45 l1 in yeast

Publications (3)

Publication Number Publication Date
BRPI0414845A BRPI0414845A (pt) 2006-11-21
BRPI0414845B1 BRPI0414845B1 (pt) 2020-10-13
BRPI0414845B8 true BRPI0414845B8 (pt) 2021-06-15

Family

ID=34421558

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0414845A BRPI0414845B8 (pt) 2003-09-29 2004-09-24 mólecula de ácido nucleico, vetor, célula de levedura, partícula semelhante a vírus, bem como método para produzir a dita partícula semelhante a vírus

Country Status (33)

Country Link
US (2) US7250170B2 (online.php)
EP (1) EP1673106B1 (online.php)
JP (4) JP5451960B2 (online.php)
KR (1) KR101165278B1 (online.php)
CN (1) CN1859923B (online.php)
AR (2) AR045804A1 (online.php)
AT (1) ATE435029T1 (online.php)
AU (1) AU2004277934B2 (online.php)
BE (1) BE2015C072I2 (online.php)
BR (1) BRPI0414845B8 (online.php)
CA (1) CA2539168C (online.php)
CY (2) CY1110525T1 (online.php)
DE (1) DE602004021828D1 (online.php)
DK (1) DK1673106T3 (online.php)
ES (1) ES2327530T3 (online.php)
FR (1) FR15C0083I2 (online.php)
HU (1) HUS1500063I1 (online.php)
IL (1) IL174458A (online.php)
IS (1) IS2694B (online.php)
LT (2) LTC1673106I2 (online.php)
LU (1) LU92902I2 (online.php)
MX (1) MXPA06003457A (online.php)
MY (1) MY140664A (online.php)
NL (1) NL300776I2 (online.php)
NO (3) NO339932B1 (online.php)
NZ (1) NZ545834A (online.php)
PL (1) PL1673106T3 (online.php)
PT (1) PT1673106E (online.php)
RU (1) RU2360001C2 (online.php)
SI (1) SI1673106T1 (online.php)
TW (1) TWI350853B (online.php)
WO (1) WO2005032586A1 (online.php)
ZA (1) ZA200601961B (online.php)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
US7858098B2 (en) * 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
MY139500A (en) 2003-11-12 2009-10-30 Merck Sharp & Dohme Optimized expression of hpv 58 l1 in yeast
BRPI0509079B8 (pt) 2004-03-24 2021-07-06 Merck & Co Inc molécula de ácido nucléico, vetor, célula hospedeira, partículas tipo vírus, método para produzir vlps, vacina, composições farmacêuticas, e, métodos para evitar infecção por hpv e para induzir uma resposta imune em um animal
US7758866B2 (en) 2004-06-16 2010-07-20 Glaxosmithkline Biologicals, S.A. Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
EP1877087B1 (en) 2005-04-15 2013-02-20 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
WO2006114312A2 (en) * 2005-04-26 2006-11-02 Glaxosmithkline Biologicals S.A. Vaccine
US8101342B2 (en) * 2006-08-28 2012-01-24 Sungkyunkwan University Foundation For Corporate Collaboration DNA vaccine for treating or preventing cervical cancer comprising a gene encoding HPV protein
CN101622008A (zh) * 2007-03-09 2010-01-06 默克公司 乳头瘤病毒疫苗组合物
EP2479187A1 (en) 2007-11-23 2012-07-25 Shanghai Zerun Biotechnology Co., Ltd. Genes encoding major capsid protein L1 of human papilloma viruses
MX2011013566A (es) 2009-06-19 2012-06-28 Eyegene Inc Vacunas para cancer cervical.
CA2799205A1 (en) 2010-05-25 2011-12-01 Qiagen Gaithersburg, Inc. Fast results hybrid capture assay and associated strategically-truncated probes
CN103717741B (zh) * 2011-06-15 2016-04-13 中央大学校产学协力团 用于提高人乳头瘤病毒l1蛋白产量的方法
KR102049988B1 (ko) 2011-06-24 2019-11-28 머크 샤프 앤드 돔 코포레이션 알루미늄 아주반트를 포함하는 hpv 백신 제제 및 그의 제조 방법
CN109321592A (zh) * 2012-01-21 2019-02-12 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv18 l1蛋白的方法
CN103361280B (zh) * 2012-03-28 2018-07-24 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv11 l1蛋白的方法
CN104120089B (zh) * 2013-04-26 2019-09-24 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv52 l1蛋白的方法
CN104120088B (zh) * 2013-04-26 2019-09-24 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv58 l1蛋白的方法
CN110295190A (zh) * 2013-05-17 2019-10-01 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv45 l1蛋白的方法
CN112280793B (zh) * 2013-09-29 2022-06-24 上海泽润生物科技有限公司 人乳头瘤病毒基因，及载体，菌株，表达方法
EP3057612B1 (en) 2013-10-16 2020-05-06 Merck Sharp & Dohme Corp. Method of obtaining thermostable dried vaccine formulations
MA40624A (fr) * 2014-09-11 2016-03-17 Cadila Healthcare Ltd Antigènes supérieurs du papillomavirus présentant des propriétés immunologiques supérieures et vaccin les contenant
CN106282278B (zh) * 2015-06-29 2021-06-08 广东东阳光药业有限公司 一种人乳头瘤病毒l1蛋白的发酵方法
CN106701798B (zh) * 2015-08-12 2021-09-17 北京康乐卫士生物技术股份有限公司 45型重组人乳头瘤病毒病毒样颗粒及其制备方法
CN109750050B (zh) * 2017-11-07 2023-08-18 上海泽润生物科技有限公司 重组人乳头瘤病毒45亚型蛋白表达
BR112022015313A2 (pt) 2020-02-14 2022-09-27 Merck Sharp & Dohme Llc Vacina de hpv
CN112680462B (zh) * 2020-12-29 2022-02-22 上海博唯生物科技有限公司 一种人乳头瘤病毒35型/hpv35型l1/l2及其制备与应用
CN113073105B (zh) * 2021-03-23 2023-06-13 重庆博唯佰泰生物制药有限公司 一种表达hpv 56l1的多核苷酸序列及其表达载体、宿主细胞和应用
AR126708A1 (es) 2021-08-06 2023-11-08 Merck Sharp & Dohme Llc Vacuna para el vph
CA3229064A1 (en) 2021-08-19 2023-02-23 Andrew Bett Thermostable lipid nanoparticle and methods of use thereof
TW202513091A (zh) 2023-06-09 2025-04-01 美商默沙東有限責任公司 用於人類乳突病毒疫苗之奈米乳液佐劑組合物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE328068T1 (de) * 1994-05-16 2006-06-15 Merck & Co Inc Papillomavirus vakzine
AR004464A1 (es) 1994-11-14 1998-12-16 Merck Sharp & Dohme Un metodo para producir una proteina de capside de papilomavirus
IL117459A (en) * 1995-03-22 2005-11-20 Merck & Co Inc Dna encoding human papillomavirus type 18
IL117591A0 (en) * 1995-03-30 1996-07-23 Merck & Co Inc Synthetic DNA encoding human papillomavirus type 11 L1 protein
CA2280195A1 (en) 1997-02-07 1998-08-13 Merck & Co., Inc. Synthetic hiv gag genes
US6391585B1 (en) * 1997-05-27 2002-05-21 Hanil Synthetic Fiber Co., Ltd. Process for preparing recombinant proteins using highly efficient expression vector from saccharomyces cerevisiae
EP1002091B1 (en) 1997-07-09 2012-02-29 Coridon Pty Limited Nucleic acid sequence and method for selectively expressing a protein in a target cell or tissue
CA2339324C (en) * 1998-08-14 2011-05-31 Robert S. Lowe Protein delivery system using human papillomavirus virus-like particles
US6991795B1 (en) * 1998-08-14 2006-01-31 Merck & Co., Inc. Protein delivery system using human papillomavirus virus-like particles
PL347472A1 (en) * 1998-08-14 2002-04-08 Merck & Co Inc Process for purifying human papillomavirus virus-like particles
EP1140974B1 (en) * 1998-12-23 2005-03-02 Merck & Co., Inc. Neutralizing assay using human papillomavirus virus-like particles
ATE284898T1 (de) * 1999-08-25 2005-01-15 Merck & Co Inc Synthetische papillomavirus gene, welche für expression in menschlichen zellen optimiert sind
US6436402B1 (en) * 1999-10-15 2002-08-20 Merck & Co., Inc. Process for making human papillomavirus virus-like particles with improved properties
US7026443B1 (en) * 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
ATE346947T1 (de) 2000-07-21 2006-12-15 Glaxo Group Ltd Kodon-optimierte papillomavirussequenzen
US7041500B2 (en) * 2002-02-14 2006-05-09 Novavax, Inc. Insect cell line
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
ES2381964T3 (es) 2003-03-24 2012-06-04 Merck Sharp & Dohme Corp. Expresión optimizada de L1 de VPH 31 en levadura

Also Published As

Publication number Publication date
TW200521233A (en) 2005-07-01
JP2011152137A (ja) 2011-08-11
LTPA2015049I1 (lt) 2016-01-11
BRPI0414845A (pt) 2006-11-21
US20060240040A1 (en) 2006-10-26
BE2015C072I2 (online.php) 2023-12-14
TWI350853B (en) 2011-10-21
JP2007507207A (ja) 2007-03-29
MY140664A (en) 2010-01-15
EP1673106B1 (en) 2009-07-01
US20080138361A1 (en) 2008-06-12
SI1673106T1 (sl) 2009-12-31
IL174458A0 (en) 2006-08-01
ES2327530T3 (es) 2009-10-30
IS8362A (is) 2006-03-20
NL300776I1 (online.php) 2015-12-29
JP2016136947A (ja) 2016-08-04
NO339932B1 (no) 2017-02-20
PT1673106E (pt) 2009-09-22
FR15C0083I2 (fr) 2016-11-25
JP2014221052A (ja) 2014-11-27
DK1673106T3 (da) 2009-11-09
ATE435029T1 (de) 2009-07-15
US7250170B2 (en) 2007-07-31
MXPA06003457A (es) 2006-06-05
IS2694B (is) 2010-11-15
KR20070029628A (ko) 2007-03-14
NO20061876L (no) 2006-04-28
CY1110525T1 (el) 2015-04-29
BRPI0414845B1 (pt) 2020-10-13
CN1859923B (zh) 2012-09-05
NO2017012I1 (no) 2017-04-05
ZA200601961B (en) 2007-05-30
RU2360001C2 (ru) 2009-06-27
WO2005032586A1 (en) 2005-04-14
CY2015050I2 (el) 2016-06-22
LU92902I2 (fr) 2016-03-08
US7482015B2 (en) 2009-01-27
JP5451960B2 (ja) 2014-03-26
KR101165278B1 (ko) 2012-07-23
RU2006114701A (ru) 2007-11-10
AU2004277934A1 (en) 2005-04-14
CN1859923A (zh) 2006-11-08
AU2004277934B2 (en) 2009-09-17
NO2022051I1 (no) 2022-11-30
LTC1673106I2 (lt) 2017-05-10
DE602004021828D1 (de) 2009-08-13
FR15C0083I1 (fr) 2016-08-01
CA2539168A1 (en) 2005-04-14
NL300776I2 (online.php) 2015-12-29
HUS1500063I1 (hu) 2016-02-29
PL1673106T3 (pl) 2009-12-31
EP1673106A1 (en) 2006-06-28
AR077396A2 (es) 2011-08-24
CA2539168C (en) 2011-05-31
IL174458A (en) 2014-06-30
CY2015050I1 (el) 2016-06-22
NZ545834A (en) 2009-02-28
AR045804A1 (es) 2005-11-16

Similar Documents

Publication Publication Date Title
BRPI0414845A (pt) mólecula de ácido nucleico, vetor, célula hospedeira, partìculas semelhantes a vìrus, método para produzir as partìculas semelhantes a vìrus, vacina, composições farmacêuticas, e, métodos para prevenir infecção por hpv e para induzir uma resposta imune em um animal
BRPI0408639B8 (pt) molécula de ácido nucleico, vetor, célula hospedeira de levedura e método para produzir partículas semelhantes a vírus de hpv31
BRPI0416393A (pt) molécula de ácido nucleico, vetor, célula hospedeira, partìculas semelhantes a vìrus, métodos para produzir as mesmas, para prevenir infecção por hpv, e para induzir uma resposta imune em um animal, vacina, composições farmacêuticas, e, polipeptìdeo hpv58 l1 isolado e purificado
BRPI0509079B8 (pt) molécula de ácido nucléico, vetor, célula hospedeira, partículas tipo vírus, método para produzir vlps, vacina, composições farmacêuticas, e, métodos para evitar infecção por hpv e para induzir uma resposta imune em um animal
Lua et al. Bioengineering virus‐like particles as vaccines
Plotkin Vaccines: past, present and future
BR112014015016A8 (pt) Proteína homodimérica de duas cadeias de aminoácidos idênticas, cadeia de aminoácido, molécula de ácido nucléico, composição farmacêutica, célula hospedeira, método de preparação de uma proteína homodimérica, método para preparação de uma vacina, vacina e método de tratamento ou prevenção
BRPI0507579A (pt) molécula de ácido nucleico, vetor, célula hospedeira, processo para expressar uma proteìna de fusão cea em uma célula hospedeira recombinante, proteìna de fusão cea purificada, método de prevenção ou tratamento de cáncer, plasmìdeo de vacina, e, método de tratamento de um mamìfero sofrendo de ou predisposto a um cáncer associados com cea
CN115927417A (zh) 无帽线性且无修饰尿苷的mRNA技术平台
WO2002074920A3 (en) A replication-defective alphavirus vaccine linking antigen with an immunogenicity-potentiating polypeptide and a method of delivery the same
ZA200806551B (en) Hepatitis C virus non structural fusion protein
CN111303251B (zh) 一种口蹄疫病毒样颗粒体外组装的方法及其应用
WO2023166314A3 (en) Rna molecule
Adhikari et al. Protein Engineering: A Novel Approach in Vaccine Development.
WO2025052108A3 (en) Rna molecule
Gokduman et al. Potential of Bovine Herpesvirus Vectors for Recombinant Vaccines
TW200607858A (en) Optimized expression of HPV 31 L1 in yeast
de la Fuente Approaching Challenges Posed by SARS-CoV-2 Genetic Variants. Pathogens 2022, 11, 1407
Wee et al. Swine Influenza Virus Recombinant HA Protein Expressed in the Baculovirus System Elicited Protective Immunity in Mice
WO2025008641A3 (en) Rna molecule
Fazeli et al. Clarification of recombinant Pichia pastoris lysate containing hepatitis B surface antigen using polyethylene glycol 6000 and acid precipitation techniques
TH82139B (th) การแสดงออกที่ถูกทำให้เหมาะสมของ hpv 45l1 ในยีสต์
MY138895A (en) Optimized expression of hpv 31 l1 in yeast

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: MERCK SHARP AND DOHME CORP. (US)

Free format text: ALTERADO DE: MERCK AND CO., INC.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: SCHERING CORPORATION, (US)

B25D Requested change of name of applicant approved

Owner name: MERCK SHARP AND DOHME CORP. (US)

B25G Requested change of headquarter approved

Owner name: MERCK SHARP AND DOHME CORP. (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 13/10/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/09/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2597 DE 13/10/2020 QUANTO AO RELATORIO DESCRITIVO.

B25A Requested transfer of rights approved

Owner name: MERCK SHARP AND DOHME LLC (US)

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 24/09/2024.